Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Cell Viability Assays Market by Product (Consumables, Instruments), by Application (Basic Research, Stem Cell Research, Drug Discovery and development, Clinical and Diagnostic Applications, Other Applications) and by End Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospital and Diagnostic Laboratories, Other End Users): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10263

Pages: NA

Charts: NA

Tables: NA

Cell Viability Assays Market Outlook - 2027

Assays are used for the measurement for cellular proliferation, cytotoxicity, and cell viability and also are used commonly for monitoring the reaction and condition of cells in the culture after various treatments are been run on them. The decision of using the right assay for the completely depends on the amount of cells and their type which helps in the final and expected outcome. Cell proliferation assays help in keeping a track on the amount of cells,cellular divisions’ numbers, activity of the metabolism, or for DNA synthesis. Counting of the cells by the useof viability dyes like Calcein-AM or trypan blue provides both the proliferation speedalong with the viable cells percentage.  

                                                      

There are various methods used in the cell viability assay process:

  1. Dyes reduced by cellular enzymes
  2. Mitochondrial membrane potential-dependent dyes
  3. Cellular esterase cleaved dyes
  4. ATP and ADP assays
  5. Glycolytic flux and oxygen consumption assays

There are also various other alternative methods and indirect methods for performing a cell viability assay measure like measuring cytotoxicity which involves counting down the number of dead or damaged cells. In some cases, apoptosis assay is used to assess cell viability.

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Cell Viability Assays market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Funds for research increasing by the manufacturers, increasing demand for the cell-based assays in the research process, and focus on the development of cell-based therapeutics is increasing and thus affecting and boosting the growth of the cell viability assay market.

Growing frequency and incidences of chronic and infectious diseases are increasing the demand for cell viability assays market. Moreover, chronic disorders cases are increasing significantly due to lifestyle changes and the geriatric population. Heart-related disorderand cancer cases are leading to the growth of death rates, reasons for these diseases being change in lifestyles, increasing cases of obesity levels, urbanization,tobacco availability easily and broadly, and frequent diet alterations. As chronic disordersare at a rise, there is a huge demand concerning assays which are helping in the faster treatment and timelydetection of the patients’ condition.

However, the assays consume a lot of time to examinethe cell viability; its incubation period is around 4 hours. The absorbance process for the detection which is predominantly used in various assays is not as effective as compared to fluorescent and luminescent methods for the detection of  theviability of cells. Hence, the viability of the cell is gettingaffected and also damages the cells till the experiment is completed. These factors are impacting the growth of the cell viability assay market negatively.

New product launches and acquisitions to flourish the market:

On April 1st, 2020, Biotek introduced a new cell count &viability starter kit which calautomaticallydo the process of cell counting and viability measurements in a mammalian cell suspension.

Surge in usage in Pharmaceutical and biotechnology companies’ applications:

Pharmaceutical and biotechnology companies are the major consumers of the cell viability assays and are expected to grow even further in the coming years. This is possible due to the increasing number of R&D activities he companies are performing which is also helping in the development of biopharmaceutical products. Along with this, hospital and diagnostic laboratories are the major end-users for the cell viability assays.

Key benefits of the report:

  • This study presents the analytical depiction of the global Cell Viability Assays industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Cell Viability Assays market share.
  • The current market is quantitatively analyzed to highlight the global Cell Viability Assays market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Cell Viability Assays market analysis based on competitive intensity and how the competition will take shape in coming years.

Key Market Segments

  • By Product
    • Consumables
      • Reagents
      • Assay Kits
        • Tetrazolium Reduction Assay Kits
          • MTT Assay Kits Other Tetrazolium Assay Kits
          • MTT Assay Kits Other Tetrazolium Assay Kits
        • Resazurin Cell Viability Assay Kits
        • Calcein-AM Cell Viability Assay Kits
        • Other Assay Kits
      • Microplates
    • Instruments
      • Spectrophotometers
      • Flow Cytometers
      • Automated Cell Counters
      • Cell Imaging and Analysis Systems
  • By Application
    • Basic Research
    • Stem Cell Research
    • Drug Discovery and development
    • Clinical and Diagnostic Applications
    • Other Applications
  • By End Users
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Hospital and Diagnostic Laboratories
    • Other End Users
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Creative Bioarray
  • Bio-Rad Laboratories
  • Becton, Dickinson and Company.
  • Promega Corporation
  • GE Healthcare
  • Merck
  • PerkinElmer
  • BioTek Instruments
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CELL VIABILITY ASSAYS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Reagents

        • 4.2.4.1. Market Size and Forecast
      • 4.2.4. Assay Kits

        • 4.2.4.1. Market Size and Forecast
        • 4.2.4.2. Tetrazolium Reduction Assay Kits

          • 4.2.4.2.1. Market Size and Forecast
          • 4.2.4.2.2. MTT Assay Kits Other Tetrazolium Assay Kits
            • 4.2.4.2.2.1. Market Size and Forecast
          • 4.2.4.2.2. MTT Assay Kits Other Tetrazolium Assay Kits
            • 4.2.4.2.2.1. Market Size and Forecast
        • 4.2.4.2. Resazurin Cell Viability Assay Kits

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Calcein-AM Cell Viability Assay Kits

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Other Assay Kits

          • 4.2.4.2.1. Market Size and Forecast
      • 4.2.4. Microplates

        • 4.2.4.1. Market Size and Forecast
    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Spectrophotometers

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Flow Cytometers

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Automated Cell Counters

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Cell Imaging and Analysis Systems

        • 4.3.4.1. Market Size and Forecast
  • CHAPTER 5: CELL VIABILITY ASSAYS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Basic Research

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Stem Cell Research

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Drug Discovery And Development

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Clinical And Diagnostic Applications

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Other Applications

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: CELL VIABILITY ASSAYS MARKET, BY END USERS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End Users

    • 6.2. Academic And Research Institutes

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmaceutical And Biotechnology Companies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Hospital And Diagnostic Laboratories

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Other End Users

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: CELL VIABILITY ASSAYS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End Users

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Cell Viability Assays Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End Users
      • 7.2.7. Canada Cell Viability Assays Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End Users
      • 7.2.8. Mexico Cell Viability Assays Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End Users
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End Users

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Cell Viability Assays Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End Users
      • 7.3.7. Germany Cell Viability Assays Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End Users
      • 7.3.8. Italy Cell Viability Assays Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End Users
      • 7.3.9. Spain Cell Viability Assays Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End Users
      • 7.3.10. UK Cell Viability Assays Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End Users
      • 7.3.11. Russia Cell Viability Assays Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End Users
      • 7.3.12. Rest Of Europe Cell Viability Assays Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End Users
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End Users

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Cell Viability Assays Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End Users
      • 7.4.7. Japan Cell Viability Assays Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End Users
      • 7.4.8. India Cell Viability Assays Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End Users
      • 7.4.9. South Korea Cell Viability Assays Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End Users
      • 7.4.10. Australia Cell Viability Assays Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End Users
      • 7.4.11. Thailand Cell Viability Assays Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End Users
      • 7.4.12. Malaysia Cell Viability Assays Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End Users
      • 7.4.13. Indonesia Cell Viability Assays Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End Users
      • 7.4.14. Rest of Asia Pacific Cell Viability Assays Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End Users
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End Users

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Cell Viability Assays Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End Users
      • 7.5.7. South Africa Cell Viability Assays Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End Users
      • 7.5.8. Saudi Arabia Cell Viability Assays Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End Users
      • 7.5.9. UAE Cell Viability Assays Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End Users
      • 7.5.10. Argentina Cell Viability Assays Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End Users
      • 7.5.11. Rest of LAMEA Cell Viability Assays Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End Users
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Thermo Fisher Scientific Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bio-Rad Laboratories

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Merck

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. GE Healthcare

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. BioTek Instruments

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. PerkinElmer

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Promega Corporation

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Creative Bioarray

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Danaher Corporation

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Becton, Dickinson And Company.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CELL VIABILITY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CELL VIABILITY ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CELL VIABILITY ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CELL VIABILITY ASSAYS MARKET FOR STEM CELL RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CELL VIABILITY ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CELL VIABILITY ASSAYS MARKET FOR CLINICAL AND DIAGNOSTIC APPLICATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL CELL VIABILITY ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL CELL VIABILITY ASSAYS MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL CELL VIABILITY ASSAYS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL CELL VIABILITY ASSAYS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL CELL VIABILITY ASSAYS MARKET FOR HOSPITAL AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL CELL VIABILITY ASSAYS MARKET FOR OTHER END USERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL CELL VIABILITY ASSAYS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA CELL VIABILITY ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 20. U.S. CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 21. U.S. CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 23. CANADA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. CANADA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE CELL VIABILITY ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 39. ITALY CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. ITALY CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 45. UK CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. UK CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC CELL VIABILITY ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 58. CHINA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 59. CHINA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 64. INDIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. INDIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA CELL VIABILITY ASSAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 98. UAE CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 99. UAE CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA CELL VIABILITY ASSAYS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA CELL VIABILITY ASSAYS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA CELL VIABILITY ASSAYS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 107. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 108. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 109. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 110. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 111. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. BIO-RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 113. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 114. BIO-RAD LABORATORIES: OPERATING SEGMENTS
  • TABLE 115. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 116. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. MERCK: KEY EXECUTIVES
  • TABLE 118. MERCK: COMPANY SNAPSHOT
  • TABLE 119. MERCK: OPERATING SEGMENTS
  • TABLE 120. MERCK: PRODUCT PORTFOLIO
  • TABLE 121. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 123. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 124. GE HEALTHCARE: OPERATING SEGMENTS
  • TABLE 125. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 126. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. BIOTEK INSTRUMENTS: KEY EXECUTIVES
  • TABLE 128. BIOTEK INSTRUMENTS: COMPANY SNAPSHOT
  • TABLE 129. BIOTEK INSTRUMENTS: OPERATING SEGMENTS
  • TABLE 130. BIOTEK INSTRUMENTS: PRODUCT PORTFOLIO
  • TABLE 131. BIOTEK INSTRUMENTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. PERKINELMER: KEY EXECUTIVES
  • TABLE 133. PERKINELMER: COMPANY SNAPSHOT
  • TABLE 134. PERKINELMER: OPERATING SEGMENTS
  • TABLE 135. PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 136. PERKINELMER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. PROMEGA CORPORATION: KEY EXECUTIVES
  • TABLE 138. PROMEGA CORPORATION: COMPANY SNAPSHOT
  • TABLE 139. PROMEGA CORPORATION: OPERATING SEGMENTS
  • TABLE 140. PROMEGA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 141. PROMEGA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. CREATIVE BIOARRAY: KEY EXECUTIVES
  • TABLE 143. CREATIVE BIOARRAY: COMPANY SNAPSHOT
  • TABLE 144. CREATIVE BIOARRAY: OPERATING SEGMENTS
  • TABLE 145. CREATIVE BIOARRAY: PRODUCT PORTFOLIO
  • TABLE 146. CREATIVE BIOARRAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 148. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 149. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 150. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 151. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. BECTON, DICKINSON AND COMPANY.: KEY EXECUTIVES
  • TABLE 153. BECTON, DICKINSON AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 154. BECTON, DICKINSON AND COMPANY.: OPERATING SEGMENTS
  • TABLE 155. BECTON, DICKINSON AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 156. BECTON, DICKINSON AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL VIABILITY ASSAYS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CELL VIABILITY ASSAYS MARKET
  • FIGURE 3. SEGMENTATION CELL VIABILITY ASSAYS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CELL VIABILITY ASSAYS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCELL VIABILITY ASSAYS MARKET
  • FIGURE 11. CELL VIABILITY ASSAYS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. CELL VIABILITY ASSAYS MARKET FOR CONSUMABLES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CELL VIABILITY ASSAYS MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CELL VIABILITY ASSAYS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. CELL VIABILITY ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. CELL VIABILITY ASSAYS MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. CELL VIABILITY ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. CELL VIABILITY ASSAYS MARKET FOR CLINICAL AND DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. CELL VIABILITY ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. CELL VIABILITY ASSAYS MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 21. CELL VIABILITY ASSAYS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. CELL VIABILITY ASSAYS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. CELL VIABILITY ASSAYS MARKET FOR HOSPITAL AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. CELL VIABILITY ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: CELL VIABILITY ASSAYS MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. BIO-RAD LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. BIO-RAD LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. BIO-RAD LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. MERCK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. MERCK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. MERCK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. GE HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. GE HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. BIOTEK INSTRUMENTS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. BIOTEK INSTRUMENTS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. BIOTEK INSTRUMENTS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. PERKINELMER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. PERKINELMER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. PERKINELMER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. PROMEGA CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. PROMEGA CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. PROMEGA CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. CREATIVE BIOARRAY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. CREATIVE BIOARRAY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. CREATIVE BIOARRAY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. BECTON, DICKINSON AND COMPANY.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Cell Viability Assays Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue